Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally

25
17
Favorite

Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally

benzinga2021-06-16

Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares. What Happened...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（17）

CkSck
·2021-06-17
Wow
Reply
Like
Report
HuiHong
·2021-06-16
nice
Reply
Like
Report
enyj
·2021-06-16
geo
Reply
Like
Report
Jackie_Woo
·2021-06-16
Good
Reply
Like
Report
Fold Replies
- charlito:
  good
  2021-06-16
  Reply
  Report
9199ni
·2021-06-16
good
Reply
2
Report
9199ni
·2021-06-16
nice
Reply
1
Report
GME1mBy2022
·2021-06-16
PLZ REPLY TO COMMENT TO WIN 9999 TRILLION DOLLARS THX
Reply
2
Report
Fold Replies
- boonchek:
  Comment back and win too! Lol
  2021-06-16
  Reply
  Report
Simba2021
·2021-06-16
??
Reply
3
Report
Vintorez
·2021-06-16
O.o
Reply
2
Report
TripleWin
·2021-06-16
Bad news
Reply
4
Report
Fold Replies
- Veldora:
  How bad is this news? Nothing much change for the company
  2021-06-16
  Reply
  Report
- VeldoraReplying toAurulentL:
  Commented
  2021-06-16
  Reply
  Report
- AurulentL:
  Comment Pls
  2021-06-16
  Reply
  Report
HyperBaka
·2021-06-16
A
Reply
1
Report
Fold Replies
- megastonks:
  nice
  2021-06-16
  Reply
  Report
Desmond669
·2021-06-16
Good read
Reply
2
Report
Fold Replies
- JZT:
  ?
  2021-06-16
  Reply
  Report
megastonks
·2021-06-16
Like
Reply
3
Report
Fold Replies
- JZT:
  ?
  2021-06-16
  Reply
  Report
Raymond杨
·2021-06-16
Nice kindly comment thank you
Reply
3
Report
Fold Replies
- JZT:
  ?
  2021-06-16
  Reply
  Report
bkohh
·2021-06-16
like
Reply
1
Report
Fold Replies
- kenta:
  wow
  2021-06-16
  Reply
  Report
Rayechia
·2021-06-16
Tell me your opinion about this news...
Reply
1
Report
Fold Replies
- bkohh:
  ok
  2021-06-16
  Reply
  Report
CollinNgu
·2021-06-16
Hmmm
Reply
1
Report
Fold Replies
- Rayechia:
  Ok
  2021-06-16
  Reply
  Report
- QQ23:
  Yup
  2021-06-16
  Reply
  Report
- LW100Replying toPrincessleo:
  Comment
  2021-06-16
  Reply
  Report
View more 1 comments

Most Discussed

7x24

All

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1150256789?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-06-16 16:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1150256789","market":"us","top_or_hot":-1,"title":"Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally","media":"benzinga","content":"<div>\n<p>Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened...</p>\n\n<a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\">Source Link</a>\n\n</div>\n","source":"lsy1606299360108","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-16 16:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally><strong>benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened...</p>\n\n<a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally","article_id":"1150256789","we_media_id":null,"thumbnails":[],"rights":{"source":"lsy1606299360108","url":"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=1150256789","pubTimestamp":1623833619,"columns":[],"sourceInfo":{"source_id":"lsy1606299360108","name":"Benzinga"},"weMediaInfo":null,"summary":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Orphazyme的主要投资者Sunstone在散户投资者推动的反弹后减持了股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ORPH":0.9},"content_text":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened: Orphazyme said on Tuesday it received a notice from Copenhagen-based Sunstone Life Science Ventures that as of June 11, funds held by Sunstone hold less than 5% of the company’s share capital.\nIn March, Orphazyme had disclosed in its annual report that Sunstone owned 5.2% of the company’s shares, according to areportby Bloomberg.\nOnly two investors — LSP V Coöperatieve U.A. with a 7.81% stake and Coöperative Aescap Venture I U.A. with a 5.1% stake — now own more than 5% of Orphazyme’s shares, the report added.\nWhy It Matters: Last week, Orphazyme emergedas one of the so-called stonks, or stocks popular with retail investors. The company’s sharesskyrocketedalmost 1,400% at one point on Thursday.\nIn a regulatory filing, Orphazyme said it isn't aware of any material change in its clinical development programs, financial condition or results of operations that would explain the price volatility in its shares that occurred since last Thursday.\nHowever, the FDA is scheduled to rule on Orphazyme's NDA for Arimocolmol for the treatment of Niemann-Pick Disease Type C, on Thursday, June 17.\nPrice Action: Orphazyme shares closed 9.5% lower in Tuesday’s trading at $10.05.","kind":"news","is_publish_news":false,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[{"id":161565775,"gmtCreate":1623935532497,"gmtModify":1703823882225,"author":{"id":"3581591880603790","authorId":"3581591880603790","name":"CkSck","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"wearingBadges":[],"authorIdStr":"3581591880603790","idStr":"3581591880603790"},"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/161565775","repostId":1150256789,"repostType":4,"repost":{"id":"1150256789","kind":"news","pubTimestamp":1623833619,"share":"https://ttm.financial/m/news/1150256789?lang=en_US&edition=fundamental","pubTime":"2021-06-16 16:53","market":"us","language":"en","title":"Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=1150256789","media":"benzinga","summary":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the","content":"<div>\n<p>Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened...</p>\n\n<a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\">Source Link</a>\n\n</div>\n","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-16 16:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally><strong>benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened...</p>\n\n<a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150256789","content_text":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened: Orphazyme said on Tuesday it received a notice from Copenhagen-based Sunstone Life Science Ventures that as of June 11, funds held by Sunstone hold less than 5% of the company’s share capital.\nIn March, Orphazyme had disclosed in its annual report that Sunstone owned 5.2% of the company’s shares, according to areportby Bloomberg.\nOnly two investors — LSP V Coöperatieve U.A. with a 7.81% stake and Coöperative Aescap Venture I U.A. with a 5.1% stake — now own more than 5% of Orphazyme’s shares, the report added.\nWhy It Matters: Last week, Orphazyme emergedas one of the so-called stonks, or stocks popular with retail investors. The company’s sharesskyrocketedalmost 1,400% at one point on Thursday.\nIn a regulatory filing, Orphazyme said it isn't aware of any material change in its clinical development programs, financial condition or results of operations that would explain the price volatility in its shares that occurred since last Thursday.\nHowever, the FDA is scheduled to rule on Orphazyme's NDA for Arimocolmol for the treatment of Niemann-Pick Disease Type C, on Thursday, June 17.\nPrice Action: Orphazyme shares closed 9.5% lower in Tuesday’s trading at $10.05.","news_type":1,"symbols_score_info":{"ORPH":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":169430424,"gmtCreate":1623846637768,"gmtModify":1703821199718,"author":{"id":"3556146747015641","authorId":"3556146747015641","name":"HuiHong","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"wearingBadges":[],"authorIdStr":"3556146747015641","idStr":"3556146747015641"},"htmlText":"nice","listText":"nice","text":"nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/169430424","repostId":1150256789,"repostType":4,"repost":{"id":"1150256789","kind":"news","pubTimestamp":1623833619,"share":"https://ttm.financial/m/news/1150256789?lang=en_US&edition=fundamental","pubTime":"2021-06-16 16:53","market":"us","language":"en","title":"Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=1150256789","media":"benzinga","summary":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the","content":"<div>\n<p>Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened...</p>\n\n<a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\">Source Link</a>\n\n</div>\n","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-16 16:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally><strong>benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened...</p>\n\n<a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150256789","content_text":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened: Orphazyme said on Tuesday it received a notice from Copenhagen-based Sunstone Life Science Ventures that as of June 11, funds held by Sunstone hold less than 5% of the company’s share capital.\nIn March, Orphazyme had disclosed in its annual report that Sunstone owned 5.2% of the company’s shares, according to areportby Bloomberg.\nOnly two investors — LSP V Coöperatieve U.A. with a 7.81% stake and Coöperative Aescap Venture I U.A. with a 5.1% stake — now own more than 5% of Orphazyme’s shares, the report added.\nWhy It Matters: Last week, Orphazyme emergedas one of the so-called stonks, or stocks popular with retail investors. The company’s sharesskyrocketedalmost 1,400% at one point on Thursday.\nIn a regulatory filing, Orphazyme said it isn't aware of any material change in its clinical development programs, financial condition or results of operations that would explain the price volatility in its shares that occurred since last Thursday.\nHowever, the FDA is scheduled to rule on Orphazyme's NDA for Arimocolmol for the treatment of Niemann-Pick Disease Type C, on Thursday, June 17.\nPrice Action: Orphazyme shares closed 9.5% lower in Tuesday’s trading at $10.05.","news_type":1,"symbols_score_info":{"ORPH":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":169593843,"gmtCreate":1623841457482,"gmtModify":1703821050089,"author":{"id":"3586783123137653","authorId":"3586783123137653","name":"enyj","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"wearingBadges":[],"authorIdStr":"3586783123137653","idStr":"3586783123137653"},"htmlText":"geo","listText":"geo","text":"geo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/169593843","repostId":1150256789,"repostType":4,"repost":{"id":"1150256789","kind":"news","pubTimestamp":1623833619,"share":"https://ttm.financial/m/news/1150256789?lang=en_US&edition=fundamental","pubTime":"2021-06-16 16:53","market":"us","language":"en","title":"Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=1150256789","media":"benzinga","summary":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the","content":"<div>\n<p>Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened...</p>\n\n<a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\">Source Link</a>\n\n</div>\n","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-16 16:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally><strong>benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened...</p>\n\n<a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150256789","content_text":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened: Orphazyme said on Tuesday it received a notice from Copenhagen-based Sunstone Life Science Ventures that as of June 11, funds held by Sunstone hold less than 5% of the company’s share capital.\nIn March, Orphazyme had disclosed in its annual report that Sunstone owned 5.2% of the company’s shares, according to areportby Bloomberg.\nOnly two investors — LSP V Coöperatieve U.A. with a 7.81% stake and Coöperative Aescap Venture I U.A. with a 5.1% stake — now own more than 5% of Orphazyme’s shares, the report added.\nWhy It Matters: Last week, Orphazyme emergedas one of the so-called stonks, or stocks popular with retail investors. The company’s sharesskyrocketedalmost 1,400% at one point on Thursday.\nIn a regulatory filing, Orphazyme said it isn't aware of any material change in its clinical development programs, financial condition or results of operations that would explain the price volatility in its shares that occurred since last Thursday.\nHowever, the FDA is scheduled to rule on Orphazyme's NDA for Arimocolmol for the treatment of Niemann-Pick Disease Type C, on Thursday, June 17.\nPrice Action: Orphazyme shares closed 9.5% lower in Tuesday’s trading at $10.05.","news_type":1,"symbols_score_info":{"ORPH":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":169210097,"gmtCreate":1623837218419,"gmtModify":1703820934348,"author":{"id":"3576668642994061","authorId":"3576668642994061","name":"Jackie_Woo","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"wearingBadges":[],"authorIdStr":"3576668642994061","idStr":"3576668642994061"},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/169210097","repostId":1150256789,"repostType":4,"repost":{"id":"1150256789","kind":"news","pubTimestamp":1623833619,"share":"https://ttm.financial/m/news/1150256789?lang=en_US&edition=fundamental","pubTime":"2021-06-16 16:53","market":"us","language":"en","title":"Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=1150256789","media":"benzinga","summary":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the","content":"<div>\n<p>Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened...</p>\n\n<a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\">Source Link</a>\n\n</div>\n","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-16 16:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally><strong>benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened...</p>\n\n<a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150256789","content_text":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened: Orphazyme said on Tuesday it received a notice from Copenhagen-based Sunstone Life Science Ventures that as of June 11, funds held by Sunstone hold less than 5% of the company’s share capital.\nIn March, Orphazyme had disclosed in its annual report that Sunstone owned 5.2% of the company’s shares, according to areportby Bloomberg.\nOnly two investors — LSP V Coöperatieve U.A. with a 7.81% stake and Coöperative Aescap Venture I U.A. with a 5.1% stake — now own more than 5% of Orphazyme’s shares, the report added.\nWhy It Matters: Last week, Orphazyme emergedas one of the so-called stonks, or stocks popular with retail investors. The company’s sharesskyrocketedalmost 1,400% at one point on Thursday.\nIn a regulatory filing, Orphazyme said it isn't aware of any material change in its clinical development programs, financial condition or results of operations that would explain the price volatility in its shares that occurred since last Thursday.\nHowever, the FDA is scheduled to rule on Orphazyme's NDA for Arimocolmol for the treatment of Niemann-Pick Disease Type C, on Thursday, June 17.\nPrice Action: Orphazyme shares closed 9.5% lower in Tuesday’s trading at $10.05.","news_type":1,"symbols_score_info":{"ORPH":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4808641,"gmtCreate":1623841153221,"gmtModify":1663229017445,"authorId":3581727570212837,"author":{"id":3581727570212837,"idStr":"3581727570212837","authorId":3581727570212837,"name":"charlito","avatar":"https://static.tigerbbs.com/187f09a2c9b9e341d7b9423366682194","vip":1,"currentWearingBadge":{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectEnabled":0,"wearingSort":0},"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[{"categoryType":1100,"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","name":"Real Trader","description":"Completed a transaction","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","isScarce":0,"effectEnabled":0,"redirectLinkEnabled":0,"redirectLinkValidityFrom":0,"redirectLinkValidityTo":9223372036854776000,"sortingWeight":0,"wearable":0}]},"repliedAuthorId":0,"objectId":169210097,"type":1,"supId":0,"prevId":0,"content":"<u>good</u>","text":"<u>good</u>","html":"<u>good</u>"}],"langContent":"EN"},{"id":169236424,"gmtCreate":1623837013768,"gmtModify":1703820929449,"author":{"id":"3583228238671976","authorId":"3583228238671976","name":"9199ni","avatar":"https://static.tigerbbs.com/8890ad4144b00eff4f6d77481bf1f859","vip":1,"crmLevel":11,"crmLevelSwitch":0,"wearingBadges":[],"authorIdStr":"3583228238671976","idStr":"3583228238671976"},"htmlText":"good","listText":"good","text":"good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/169236424","repostId":1150256789,"repostType":4,"repost":{"id":"1150256789","kind":"news","pubTimestamp":1623833619,"share":"https://ttm.financial/m/news/1150256789?lang=en_US&edition=fundamental","pubTime":"2021-06-16 16:53","market":"us","language":"en","title":"Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=1150256789","media":"benzinga","summary":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the","content":"<div>\n<p>Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened...</p>\n\n<a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\">Source Link</a>\n\n</div>\n","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-16 16:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally><strong>benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened...</p>\n\n<a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150256789","content_text":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened: Orphazyme said on Tuesday it received a notice from Copenhagen-based Sunstone Life Science Ventures that as of June 11, funds held by Sunstone hold less than 5% of the company’s share capital.\nIn March, Orphazyme had disclosed in its annual report that Sunstone owned 5.2% of the company’s shares, according to areportby Bloomberg.\nOnly two investors — LSP V Coöperatieve U.A. with a 7.81% stake and Coöperative Aescap Venture I U.A. with a 5.1% stake — now own more than 5% of Orphazyme’s shares, the report added.\nWhy It Matters: Last week, Orphazyme emergedas one of the so-called stonks, or stocks popular with retail investors. The company’s sharesskyrocketedalmost 1,400% at one point on Thursday.\nIn a regulatory filing, Orphazyme said it isn't aware of any material change in its clinical development programs, financial condition or results of operations that would explain the price volatility in its shares that occurred since last Thursday.\nHowever, the FDA is scheduled to rule on Orphazyme's NDA for Arimocolmol for the treatment of Niemann-Pick Disease Type C, on Thursday, June 17.\nPrice Action: Orphazyme shares closed 9.5% lower in Tuesday’s trading at $10.05.","news_type":1,"symbols_score_info":{"ORPH":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":169236914,"gmtCreate":1623836990438,"gmtModify":1703820927810,"author":{"id":"3583228238671976","authorId":"3583228238671976","name":"9199ni","avatar":"https://static.tigerbbs.com/8890ad4144b00eff4f6d77481bf1f859","vip":1,"crmLevel":11,"crmLevelSwitch":0,"wearingBadges":[],"authorIdStr":"3583228238671976","idStr":"3583228238671976"},"htmlText":"nice","listText":"nice","text":"nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/169236914","repostId":1150256789,"repostType":4,"repost":{"id":"1150256789","kind":"news","pubTimestamp":1623833619,"share":"https://ttm.financial/m/news/1150256789?lang=en_US&edition=fundamental","pubTime":"2021-06-16 16:53","market":"us","language":"en","title":"Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=1150256789","media":"benzinga","summary":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the","content":"<div>\n<p>Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened...</p>\n\n<a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\">Source Link</a>\n\n</div>\n","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-16 16:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally><strong>benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened...</p>\n\n<a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150256789","content_text":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened: Orphazyme said on Tuesday it received a notice from Copenhagen-based Sunstone Life Science Ventures that as of June 11, funds held by Sunstone hold less than 5% of the company’s share capital.\nIn March, Orphazyme had disclosed in its annual report that Sunstone owned 5.2% of the company’s shares, according to areportby Bloomberg.\nOnly two investors — LSP V Coöperatieve U.A. with a 7.81% stake and Coöperative Aescap Venture I U.A. with a 5.1% stake — now own more than 5% of Orphazyme’s shares, the report added.\nWhy It Matters: Last week, Orphazyme emergedas one of the so-called stonks, or stocks popular with retail investors. The company’s sharesskyrocketedalmost 1,400% at one point on Thursday.\nIn a regulatory filing, Orphazyme said it isn't aware of any material change in its clinical development programs, financial condition or results of operations that would explain the price volatility in its shares that occurred since last Thursday.\nHowever, the FDA is scheduled to rule on Orphazyme's NDA for Arimocolmol for the treatment of Niemann-Pick Disease Type C, on Thursday, June 17.\nPrice Action: Orphazyme shares closed 9.5% lower in Tuesday’s trading at $10.05.","news_type":1,"symbols_score_info":{"ORPH":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":169679307,"gmtCreate":1623835180909,"gmtModify":1703820881631,"author":{"id":"3575188872322547","authorId":"3575188872322547","name":"GME1mBy2022","avatar":"https://static.tigerbbs.com/9b0ea54290166f528c67da36f0e46841","vip":1,"crmLevel":11,"crmLevelSwitch":0,"wearingBadges":[],"authorIdStr":"3575188872322547","idStr":"3575188872322547"},"htmlText":"PLZ REPLY TO COMMENT TO WIN 9999 TRILLION DOLLARS THX&nbsp;","listText":"PLZ REPLY TO COMMENT TO WIN 9999 TRILLION DOLLARS THX&nbsp;","text":"PLZ REPLY TO COMMENT TO WIN 9999 TRILLION DOLLARS THX","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/169679307","repostId":1150256789,"repostType":4,"repost":{"id":"1150256789","kind":"news","pubTimestamp":1623833619,"share":"https://ttm.financial/m/news/1150256789?lang=en_US&edition=fundamental","pubTime":"2021-06-16 16:53","market":"us","language":"en","title":"Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=1150256789","media":"benzinga","summary":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the","content":"<div>\n<p>Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened...</p>\n\n<a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\">Source Link</a>\n\n</div>\n","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-16 16:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally><strong>benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened...</p>\n\n<a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150256789","content_text":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened: Orphazyme said on Tuesday it received a notice from Copenhagen-based Sunstone Life Science Ventures that as of June 11, funds held by Sunstone hold less than 5% of the company’s share capital.\nIn March, Orphazyme had disclosed in its annual report that Sunstone owned 5.2% of the company’s shares, according to areportby Bloomberg.\nOnly two investors — LSP V Coöperatieve U.A. with a 7.81% stake and Coöperative Aescap Venture I U.A. with a 5.1% stake — now own more than 5% of Orphazyme’s shares, the report added.\nWhy It Matters: Last week, Orphazyme emergedas one of the so-called stonks, or stocks popular with retail investors. The company’s sharesskyrocketedalmost 1,400% at one point on Thursday.\nIn a regulatory filing, Orphazyme said it isn't aware of any material change in its clinical development programs, financial condition or results of operations that would explain the price volatility in its shares that occurred since last Thursday.\nHowever, the FDA is scheduled to rule on Orphazyme's NDA for Arimocolmol for the treatment of Niemann-Pick Disease Type C, on Thursday, June 17.\nPrice Action: Orphazyme shares closed 9.5% lower in Tuesday’s trading at $10.05.","news_type":1,"symbols_score_info":{"ORPH":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4807277,"gmtCreate":1623835505044,"gmtModify":1635316664444,"authorId":3582036219515358,"author":{"id":3582036219515358,"idStr":"3582036219515358","authorId":3582036219515358,"name":"boonchek","avatar":"https://static.tigerbbs.com/c615abbfde8feafcbdd8e88179f1e152","vip":1,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":"80.36%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectEnabled":0,"wearingSort":0},"crmLevel":11,"crmLevelSwitch":1,"individualDisplayBadges":[],"wearingBadges":[{"categoryType":1100,"badgeId":"972123088c9646f7b6091ae0662215be-2","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","isScarce":0,"effectEnabled":0,"redirectLinkEnabled":0,"redirectLinkValidityFrom":0,"redirectLinkValidityTo":9223372036854776000,"sortingWeight":0,"wearable":0}]},"repliedAuthorId":0,"objectId":169679307,"type":1,"supId":0,"prevId":0,"content":"Comment back and win too! Lol","text":"Comment back and win too! Lol","html":"Comment back and win too! Lol"}],"langContent":"EN"},{"id":169647016,"gmtCreate":1623835070435,"gmtModify":1703820878976,"author":{"id":"3579251645799474","authorId":"3579251645799474","name":"Simba2021","avatar":"https://static.tigerbbs.com/f0d951f7cf49cd1f3cdd6f0d1a470ca5","vip":1,"crmLevel":11,"crmLevelSwitch":0,"wearingBadges":[],"authorIdStr":"3579251645799474","idStr":"3579251645799474"},"htmlText":"??","listText":"??","text":"??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/169647016","repostId":1150256789,"repostType":4,"repost":{"id":"1150256789","kind":"news","pubTimestamp":1623833619,"share":"https://ttm.financial/m/news/1150256789?lang=en_US&edition=fundamental","pubTime":"2021-06-16 16:53","market":"us","language":"en","title":"Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=1150256789","media":"benzinga","summary":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the","content":"<div>\n<p>Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened...</p>\n\n<a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\">Source Link</a>\n\n</div>\n","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-16 16:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally><strong>benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened...</p>\n\n<a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150256789","content_text":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened: Orphazyme said on Tuesday it received a notice from Copenhagen-based Sunstone Life Science Ventures that as of June 11, funds held by Sunstone hold less than 5% of the company’s share capital.\nIn March, Orphazyme had disclosed in its annual report that Sunstone owned 5.2% of the company’s shares, according to areportby Bloomberg.\nOnly two investors — LSP V Coöperatieve U.A. with a 7.81% stake and Coöperative Aescap Venture I U.A. with a 5.1% stake — now own more than 5% of Orphazyme’s shares, the report added.\nWhy It Matters: Last week, Orphazyme emergedas one of the so-called stonks, or stocks popular with retail investors. The company’s sharesskyrocketedalmost 1,400% at one point on Thursday.\nIn a regulatory filing, Orphazyme said it isn't aware of any material change in its clinical development programs, financial condition or results of operations that would explain the price volatility in its shares that occurred since last Thursday.\nHowever, the FDA is scheduled to rule on Orphazyme's NDA for Arimocolmol for the treatment of Niemann-Pick Disease Type C, on Thursday, June 17.\nPrice Action: Orphazyme shares closed 9.5% lower in Tuesday’s trading at $10.05.","news_type":1,"symbols_score_info":{"ORPH":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":169659949,"gmtCreate":1623834170981,"gmtModify":1703820855644,"author":{"id":"3584264973093876","authorId":"3584264973093876","name":"Vintorez","avatar":"https://static.tigerbbs.com/b8c87d9b4d20796c59a4630f150f1d35","vip":1,"crmLevel":11,"crmLevelSwitch":0,"wearingBadges":[],"authorIdStr":"3584264973093876","idStr":"3584264973093876"},"htmlText":"O.o","listText":"O.o","text":"O.o","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/169659949","repostId":1150256789,"repostType":4,"repost":{"id":"1150256789","kind":"news","pubTimestamp":1623833619,"share":"https://ttm.financial/m/news/1150256789?lang=en_US&edition=fundamental","pubTime":"2021-06-16 16:53","market":"us","language":"en","title":"Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=1150256789","media":"benzinga","summary":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the","content":"<div>\n<p>Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened...</p>\n\n<a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\">Source Link</a>\n\n</div>\n","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-16 16:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally><strong>benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened...</p>\n\n<a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150256789","content_text":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened: Orphazyme said on Tuesday it received a notice from Copenhagen-based Sunstone Life Science Ventures that as of June 11, funds held by Sunstone hold less than 5% of the company’s share capital.\nIn March, Orphazyme had disclosed in its annual report that Sunstone owned 5.2% of the company’s shares, according to areportby Bloomberg.\nOnly two investors — LSP V Coöperatieve U.A. with a 7.81% stake and Coöperative Aescap Venture I U.A. with a 5.1% stake — now own more than 5% of Orphazyme’s shares, the report added.\nWhy It Matters: Last week, Orphazyme emergedas one of the so-called stonks, or stocks popular with retail investors. The company’s sharesskyrocketedalmost 1,400% at one point on Thursday.\nIn a regulatory filing, Orphazyme said it isn't aware of any material change in its clinical development programs, financial condition or results of operations that would explain the price volatility in its shares that occurred since last Thursday.\nHowever, the FDA is scheduled to rule on Orphazyme's NDA for Arimocolmol for the treatment of Niemann-Pick Disease Type C, on Thursday, June 17.\nPrice Action: Orphazyme shares closed 9.5% lower in Tuesday’s trading at $10.05.","news_type":1,"symbols_score_info":{"ORPH":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":169624850,"gmtCreate":1623834031070,"gmtModify":1703820851897,"author":{"id":"3577489740102994","authorId":"3577489740102994","name":"TripleWin","avatar":"https://static.tigerbbs.com/36f6d7690fd546416bd6f74b156c218f","vip":1,"crmLevel":11,"crmLevelSwitch":0,"wearingBadges":[],"authorIdStr":"3577489740102994","idStr":"3577489740102994"},"htmlText":"Bad news","listText":"Bad news","text":"Bad news","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/169624850","repostId":1150256789,"repostType":4,"repost":{"id":"1150256789","kind":"news","pubTimestamp":1623833619,"share":"https://ttm.financial/m/news/1150256789?lang=en_US&edition=fundamental","pubTime":"2021-06-16 16:53","market":"us","language":"en","title":"Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=1150256789","media":"benzinga","summary":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the","content":"<div>\n<p>Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened...</p>\n\n<a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\">Source Link</a>\n\n</div>\n","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-16 16:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally><strong>benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened...</p>\n\n<a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150256789","content_text":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened: Orphazyme said on Tuesday it received a notice from Copenhagen-based Sunstone Life Science Ventures that as of June 11, funds held by Sunstone hold less than 5% of the company’s share capital.\nIn March, Orphazyme had disclosed in its annual report that Sunstone owned 5.2% of the company’s shares, according to areportby Bloomberg.\nOnly two investors — LSP V Coöperatieve U.A. with a 7.81% stake and Coöperative Aescap Venture I U.A. with a 5.1% stake — now own more than 5% of Orphazyme’s shares, the report added.\nWhy It Matters: Last week, Orphazyme emergedas one of the so-called stonks, or stocks popular with retail investors. The company’s sharesskyrocketedalmost 1,400% at one point on Thursday.\nIn a regulatory filing, Orphazyme said it isn't aware of any material change in its clinical development programs, financial condition or results of operations that would explain the price volatility in its shares that occurred since last Thursday.\nHowever, the FDA is scheduled to rule on Orphazyme's NDA for Arimocolmol for the treatment of Niemann-Pick Disease Type C, on Thursday, June 17.\nPrice Action: Orphazyme shares closed 9.5% lower in Tuesday’s trading at $10.05.","news_type":1,"symbols_score_info":{"ORPH":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4806878,"gmtCreate":1623834133347,"gmtModify":1663229011545,"authorId":3580473686930895,"author":{"id":3580473686930895,"idStr":"3580473686930895","authorId":3580473686930895,"name":"Veldora","avatar":"https://static.tigerbbs.com/2c60768e017f3418615cd7dea3a291ec","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":169624850,"type":1,"supId":0,"prevId":0,"content":"How bad is this news? Nothing much change for the company","text":"How bad is this news? Nothing much change for the company","html":"How bad is this news? Nothing much change for the company"},{"id":4806931,"gmtCreate":1623834316935,"gmtModify":1663229011246,"authorId":3580473686930895,"author":{"id":3580473686930895,"idStr":"3580473686930895","authorId":3580473686930895,"name":"Veldora","avatar":"https://static.tigerbbs.com/2c60768e017f3418615cd7dea3a291ec","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":3581585314538349,"repliedAuthor":{"id":3581585314538349,"idStr":"3581585314538349","authorId":3581585314538349,"name":"AurulentL","avatar":"https://static.tigerbbs.com/4868228f6b994364c7acca908458c7ec","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"objectId":169624850,"type":1,"supId":4806878,"prevId":4806886,"content":"Commented","text":"Commented","html":"Commented"},{"id":4806886,"gmtCreate":1623834151149,"gmtModify":1663229010831,"authorId":3581585314538349,"author":{"id":3581585314538349,"idStr":"3581585314538349","authorId":3581585314538349,"name":"AurulentL","avatar":"https://static.tigerbbs.com/4868228f6b994364c7acca908458c7ec","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":169624850,"type":1,"supId":4806878,"prevId":0,"content":"Comment Pls","text":"Comment Pls","html":"Comment Pls"}],"langContent":"EN"},{"id":169628763,"gmtCreate":1623833886852,"gmtModify":1703820848301,"author":{"id":"3566081983681494","authorId":"3566081983681494","name":"HyperBaka","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"wearingBadges":[],"authorIdStr":"3566081983681494","idStr":"3566081983681494"},"htmlText":"A","listText":"A","text":"A","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/169628763","repostId":1150256789,"repostType":4,"repost":{"id":"1150256789","kind":"news","pubTimestamp":1623833619,"share":"https://ttm.financial/m/news/1150256789?lang=en_US&edition=fundamental","pubTime":"2021-06-16 16:53","market":"us","language":"en","title":"Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=1150256789","media":"benzinga","summary":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the","content":"<div>\n<p>Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened...</p>\n\n<a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\">Source Link</a>\n\n</div>\n","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-16 16:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally><strong>benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened...</p>\n\n<a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150256789","content_text":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened: Orphazyme said on Tuesday it received a notice from Copenhagen-based Sunstone Life Science Ventures that as of June 11, funds held by Sunstone hold less than 5% of the company’s share capital.\nIn March, Orphazyme had disclosed in its annual report that Sunstone owned 5.2% of the company’s shares, according to areportby Bloomberg.\nOnly two investors — LSP V Coöperatieve U.A. with a 7.81% stake and Coöperative Aescap Venture I U.A. with a 5.1% stake — now own more than 5% of Orphazyme’s shares, the report added.\nWhy It Matters: Last week, Orphazyme emergedas one of the so-called stonks, or stocks popular with retail investors. The company’s sharesskyrocketedalmost 1,400% at one point on Thursday.\nIn a regulatory filing, Orphazyme said it isn't aware of any material change in its clinical development programs, financial condition or results of operations that would explain the price volatility in its shares that occurred since last Thursday.\nHowever, the FDA is scheduled to rule on Orphazyme's NDA for Arimocolmol for the treatment of Niemann-Pick Disease Type C, on Thursday, June 17.\nPrice Action: Orphazyme shares closed 9.5% lower in Tuesday’s trading at $10.05.","news_type":1,"symbols_score_info":{"ORPH":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4806816,"gmtCreate":1623833911885,"gmtModify":1663229011532,"authorId":3567894781486535,"author":{"id":3567894781486535,"idStr":"3567894781486535","authorId":3567894781486535,"name":"megastonks","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.08.13","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectEnabled":0,"wearingSort":0},"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":169628763,"type":1,"supId":0,"prevId":0,"content":"nice","text":"nice","html":"nice"}],"langContent":"EN"},{"id":169628593,"gmtCreate":1623833880912,"gmtModify":1703820847973,"author":{"id":"3562118563279867","authorId":"3562118563279867","name":"Desmond669","avatar":"https://static.tigerbbs.com/e2484115c94d3471cb46f20ea7598b4a","vip":1,"crmLevel":11,"crmLevelSwitch":0,"wearingBadges":[],"authorIdStr":"3562118563279867","idStr":"3562118563279867"},"htmlText":"Good read","listText":"Good read","text":"Good read","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/169628593","repostId":1150256789,"repostType":4,"repost":{"id":"1150256789","kind":"news","pubTimestamp":1623833619,"share":"https://ttm.financial/m/news/1150256789?lang=en_US&edition=fundamental","pubTime":"2021-06-16 16:53","market":"us","language":"en","title":"Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=1150256789","media":"benzinga","summary":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the","content":"<div>\n<p>Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened...</p>\n\n<a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\">Source Link</a>\n\n</div>\n","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-16 16:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally><strong>benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened...</p>\n\n<a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150256789","content_text":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened: Orphazyme said on Tuesday it received a notice from Copenhagen-based Sunstone Life Science Ventures that as of June 11, funds held by Sunstone hold less than 5% of the company’s share capital.\nIn March, Orphazyme had disclosed in its annual report that Sunstone owned 5.2% of the company’s shares, according to areportby Bloomberg.\nOnly two investors — LSP V Coöperatieve U.A. with a 7.81% stake and Coöperative Aescap Venture I U.A. with a 5.1% stake — now own more than 5% of Orphazyme’s shares, the report added.\nWhy It Matters: Last week, Orphazyme emergedas one of the so-called stonks, or stocks popular with retail investors. The company’s sharesskyrocketedalmost 1,400% at one point on Thursday.\nIn a regulatory filing, Orphazyme said it isn't aware of any material change in its clinical development programs, financial condition or results of operations that would explain the price volatility in its shares that occurred since last Thursday.\nHowever, the FDA is scheduled to rule on Orphazyme's NDA for Arimocolmol for the treatment of Niemann-Pick Disease Type C, on Thursday, June 17.\nPrice Action: Orphazyme shares closed 9.5% lower in Tuesday’s trading at $10.05.","news_type":1,"symbols_score_info":{"ORPH":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4806819,"gmtCreate":1623833915134,"gmtModify":1663229010630,"authorId":3561620162335246,"author":{"id":3561620162335246,"idStr":"3561620162335246","authorId":3561620162335246,"name":"JZT","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":169628593,"type":1,"supId":0,"prevId":0,"content":"?","text":"?","html":"?"}],"langContent":"EN"},{"id":169628951,"gmtCreate":1623833850973,"gmtModify":1703820847318,"author":{"id":"3567894781486535","authorId":"3567894781486535","name":"megastonks","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":12,"crmLevelSwitch":0,"wearingBadges":[],"authorIdStr":"3567894781486535","idStr":"3567894781486535"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/169628951","repostId":1150256789,"repostType":4,"repost":{"id":"1150256789","kind":"news","pubTimestamp":1623833619,"share":"https://ttm.financial/m/news/1150256789?lang=en_US&edition=fundamental","pubTime":"2021-06-16 16:53","market":"us","language":"en","title":"Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=1150256789","media":"benzinga","summary":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the","content":"<div>\n<p>Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened...</p>\n\n<a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\">Source Link</a>\n\n</div>\n","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-16 16:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally><strong>benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened...</p>\n\n<a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150256789","content_text":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened: Orphazyme said on Tuesday it received a notice from Copenhagen-based Sunstone Life Science Ventures that as of June 11, funds held by Sunstone hold less than 5% of the company’s share capital.\nIn March, Orphazyme had disclosed in its annual report that Sunstone owned 5.2% of the company’s shares, according to areportby Bloomberg.\nOnly two investors — LSP V Coöperatieve U.A. with a 7.81% stake and Coöperative Aescap Venture I U.A. with a 5.1% stake — now own more than 5% of Orphazyme’s shares, the report added.\nWhy It Matters: Last week, Orphazyme emergedas one of the so-called stonks, or stocks popular with retail investors. The company’s sharesskyrocketedalmost 1,400% at one point on Thursday.\nIn a regulatory filing, Orphazyme said it isn't aware of any material change in its clinical development programs, financial condition or results of operations that would explain the price volatility in its shares that occurred since last Thursday.\nHowever, the FDA is scheduled to rule on Orphazyme's NDA for Arimocolmol for the treatment of Niemann-Pick Disease Type C, on Thursday, June 17.\nPrice Action: Orphazyme shares closed 9.5% lower in Tuesday’s trading at $10.05.","news_type":1,"symbols_score_info":{"ORPH":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4806805,"gmtCreate":1623833888257,"gmtModify":1663229011547,"authorId":3561620162335246,"author":{"id":3561620162335246,"idStr":"3561620162335246","authorId":3561620162335246,"name":"JZT","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":169628951,"type":1,"supId":0,"prevId":0,"content":"?","text":"?","html":"?"}],"langContent":"EN"},{"id":169621749,"gmtCreate":1623833839381,"gmtModify":1703820846670,"author":{"id":"3560481430779928","authorId":"3560481430779928","name":"Raymond杨","avatar":"https://static.tigerbbs.com/a0e904d9a1021ec74841e99e765cf608","vip":1,"crmLevel":11,"crmLevelSwitch":0,"wearingBadges":[],"authorIdStr":"3560481430779928","idStr":"3560481430779928"},"htmlText":"Nice kindly comment thank you","listText":"Nice kindly comment thank you","text":"Nice kindly comment thank you","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/169621749","repostId":1150256789,"repostType":4,"repost":{"id":"1150256789","kind":"news","pubTimestamp":1623833619,"share":"https://ttm.financial/m/news/1150256789?lang=en_US&edition=fundamental","pubTime":"2021-06-16 16:53","market":"us","language":"en","title":"Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=1150256789","media":"benzinga","summary":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the","content":"<div>\n<p>Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened...</p>\n\n<a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\">Source Link</a>\n\n</div>\n","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-16 16:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally><strong>benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened...</p>\n\n<a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150256789","content_text":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened: Orphazyme said on Tuesday it received a notice from Copenhagen-based Sunstone Life Science Ventures that as of June 11, funds held by Sunstone hold less than 5% of the company’s share capital.\nIn March, Orphazyme had disclosed in its annual report that Sunstone owned 5.2% of the company’s shares, according to areportby Bloomberg.\nOnly two investors — LSP V Coöperatieve U.A. with a 7.81% stake and Coöperative Aescap Venture I U.A. with a 5.1% stake — now own more than 5% of Orphazyme’s shares, the report added.\nWhy It Matters: Last week, Orphazyme emergedas one of the so-called stonks, or stocks popular with retail investors. The company’s sharesskyrocketedalmost 1,400% at one point on Thursday.\nIn a regulatory filing, Orphazyme said it isn't aware of any material change in its clinical development programs, financial condition or results of operations that would explain the price volatility in its shares that occurred since last Thursday.\nHowever, the FDA is scheduled to rule on Orphazyme's NDA for Arimocolmol for the treatment of Niemann-Pick Disease Type C, on Thursday, June 17.\nPrice Action: Orphazyme shares closed 9.5% lower in Tuesday’s trading at $10.05.","news_type":1,"symbols_score_info":{"ORPH":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4806812,"gmtCreate":1623833903362,"gmtModify":1663229012427,"authorId":3561620162335246,"author":{"id":3561620162335246,"idStr":"3561620162335246","authorId":3561620162335246,"name":"JZT","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":169621749,"type":1,"supId":0,"prevId":0,"content":"?","text":"?","html":"?"}],"langContent":"EN"},{"id":169621213,"gmtCreate":1623833836132,"gmtModify":1703820846508,"author":{"id":"3581750840520859","authorId":"3581750840520859","name":"bkohh","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"wearingBadges":[],"authorIdStr":"3581750840520859","idStr":"3581750840520859"},"htmlText":"like","listText":"like","text":"like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/169621213","repostId":1150256789,"repostType":4,"repost":{"id":"1150256789","kind":"news","pubTimestamp":1623833619,"share":"https://ttm.financial/m/news/1150256789?lang=en_US&edition=fundamental","pubTime":"2021-06-16 16:53","market":"us","language":"en","title":"Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=1150256789","media":"benzinga","summary":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the","content":"<div>\n<p>Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened...</p>\n\n<a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\">Source Link</a>\n\n</div>\n","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-16 16:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally><strong>benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened...</p>\n\n<a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150256789","content_text":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened: Orphazyme said on Tuesday it received a notice from Copenhagen-based Sunstone Life Science Ventures that as of June 11, funds held by Sunstone hold less than 5% of the company’s share capital.\nIn March, Orphazyme had disclosed in its annual report that Sunstone owned 5.2% of the company’s shares, according to areportby Bloomberg.\nOnly two investors — LSP V Coöperatieve U.A. with a 7.81% stake and Coöperative Aescap Venture I U.A. with a 5.1% stake — now own more than 5% of Orphazyme’s shares, the report added.\nWhy It Matters: Last week, Orphazyme emergedas one of the so-called stonks, or stocks popular with retail investors. The company’s sharesskyrocketedalmost 1,400% at one point on Thursday.\nIn a regulatory filing, Orphazyme said it isn't aware of any material change in its clinical development programs, financial condition or results of operations that would explain the price volatility in its shares that occurred since last Thursday.\nHowever, the FDA is scheduled to rule on Orphazyme's NDA for Arimocolmol for the treatment of Niemann-Pick Disease Type C, on Thursday, June 17.\nPrice Action: Orphazyme shares closed 9.5% lower in Tuesday’s trading at $10.05.","news_type":1,"symbols_score_info":{"ORPH":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4806848,"gmtCreate":1623834018198,"gmtModify":1663229010627,"authorId":3570536834617523,"author":{"id":3570536834617523,"idStr":"3570536834617523","authorId":3570536834617523,"name":"kenta","avatar":"https://static.tigerbbs.com/4593b44a03124dfaa74fc1d7d7ff0b35","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":169621213,"type":1,"supId":0,"prevId":0,"content":"<u>wow</u>","text":"<u>wow</u>","html":"<u>wow</u>"}],"langContent":"EN"},{"id":169621611,"gmtCreate":1623833830133,"gmtModify":1703820846182,"author":{"id":"3574937196457388","authorId":"3574937196457388","name":"Rayechia","avatar":"https://community-static.tradeup.com/news/ecc1ed60635b35d8c2454c25ee862016","vip":1,"crmLevel":12,"crmLevelSwitch":0,"wearingBadges":[],"authorIdStr":"3574937196457388","idStr":"3574937196457388"},"htmlText":"Tell me your opinion about this news...","listText":"Tell me your opinion about this news...","text":"Tell me your opinion about this news...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/169621611","repostId":1150256789,"repostType":4,"repost":{"id":"1150256789","kind":"news","pubTimestamp":1623833619,"share":"https://ttm.financial/m/news/1150256789?lang=en_US&edition=fundamental","pubTime":"2021-06-16 16:53","market":"us","language":"en","title":"Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=1150256789","media":"benzinga","summary":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the","content":"<div>\n<p>Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened...</p>\n\n<a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\">Source Link</a>\n\n</div>\n","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-16 16:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally><strong>benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened...</p>\n\n<a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150256789","content_text":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened: Orphazyme said on Tuesday it received a notice from Copenhagen-based Sunstone Life Science Ventures that as of June 11, funds held by Sunstone hold less than 5% of the company’s share capital.\nIn March, Orphazyme had disclosed in its annual report that Sunstone owned 5.2% of the company’s shares, according to areportby Bloomberg.\nOnly two investors — LSP V Coöperatieve U.A. with a 7.81% stake and Coöperative Aescap Venture I U.A. with a 5.1% stake — now own more than 5% of Orphazyme’s shares, the report added.\nWhy It Matters: Last week, Orphazyme emergedas one of the so-called stonks, or stocks popular with retail investors. The company’s sharesskyrocketedalmost 1,400% at one point on Thursday.\nIn a regulatory filing, Orphazyme said it isn't aware of any material change in its clinical development programs, financial condition or results of operations that would explain the price volatility in its shares that occurred since last Thursday.\nHowever, the FDA is scheduled to rule on Orphazyme's NDA for Arimocolmol for the treatment of Niemann-Pick Disease Type C, on Thursday, June 17.\nPrice Action: Orphazyme shares closed 9.5% lower in Tuesday’s trading at $10.05.","news_type":1,"symbols_score_info":{"ORPH":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4806787,"gmtCreate":1623833848849,"gmtModify":1663229008439,"authorId":3581750840520859,"author":{"id":3581750840520859,"idStr":"3581750840520859","authorId":3581750840520859,"name":"bkohh","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":169621611,"type":1,"supId":0,"prevId":0,"content":"ok","text":"ok","html":"ok"}],"langContent":"EN"},{"id":169623800,"gmtCreate":1623833797600,"gmtModify":1703820844699,"author":{"id":"3549779044737399","authorId":"3549779044737399","name":"CollinNgu","avatar":"https://static.tigerbbs.com/3445861095aeb1d5cf3bf64b420c060c","vip":1,"hat":"https://static.tigerbbs.com/0a8758340a08196056f8bc1e54805193","crmLevel":12,"crmLevelSwitch":1,"wearingBadges":[],"authorIdStr":"3549779044737399","idStr":"3549779044737399"},"htmlText":"Hmmm","listText":"Hmmm","text":"Hmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/169623800","repostId":1150256789,"repostType":4,"repost":{"id":"1150256789","kind":"news","pubTimestamp":1623833619,"share":"https://ttm.financial/m/news/1150256789?lang=en_US&edition=fundamental","pubTime":"2021-06-16 16:53","market":"us","language":"en","title":"Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=1150256789","media":"benzinga","summary":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the","content":"<div>\n<p>Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened...</p>\n\n<a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\">Source Link</a>\n\n</div>\n","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-16 16:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally><strong>benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened...</p>\n\n<a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150256789","content_text":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened: Orphazyme said on Tuesday it received a notice from Copenhagen-based Sunstone Life Science Ventures that as of June 11, funds held by Sunstone hold less than 5% of the company’s share capital.\nIn March, Orphazyme had disclosed in its annual report that Sunstone owned 5.2% of the company’s shares, according to areportby Bloomberg.\nOnly two investors — LSP V Coöperatieve U.A. with a 7.81% stake and Coöperative Aescap Venture I U.A. with a 5.1% stake — now own more than 5% of Orphazyme’s shares, the report added.\nWhy It Matters: Last week, Orphazyme emergedas one of the so-called stonks, or stocks popular with retail investors. The company’s sharesskyrocketedalmost 1,400% at one point on Thursday.\nIn a regulatory filing, Orphazyme said it isn't aware of any material change in its clinical development programs, financial condition or results of operations that would explain the price volatility in its shares that occurred since last Thursday.\nHowever, the FDA is scheduled to rule on Orphazyme's NDA for Arimocolmol for the treatment of Niemann-Pick Disease Type C, on Thursday, June 17.\nPrice Action: Orphazyme shares closed 9.5% lower in Tuesday’s trading at $10.05.","news_type":1,"symbols_score_info":{"ORPH":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4806799,"gmtCreate":1623833871782,"gmtModify":1663229011644,"authorId":3574937196457388,"author":{"id":3574937196457388,"idStr":"3574937196457388","authorId":3574937196457388,"name":"Rayechia","avatar":"https://community-static.tradeup.com/news/ecc1ed60635b35d8c2454c25ee862016","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":169623800,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"},{"id":4806780,"gmtCreate":1623833829235,"gmtModify":1663229011445,"authorId":3582190252904748,"author":{"id":3582190252904748,"idStr":"3582190252904748","authorId":3582190252904748,"name":"QQ23","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":169623800,"type":1,"supId":0,"prevId":0,"content":"<u>Yup</u>","text":"<u>Yup</u>","html":"<u>Yup</u>"},{"id":4806916,"gmtCreate":1623834261395,"gmtModify":1663229010548,"authorId":3574320588413401,"author":{"id":3574320588413401,"idStr":"3574320588413401","authorId":3574320588413401,"name":"LW100","avatar":"https://static.tigerbbs.com/5b57af0729a9fd62bb8bac5304505b9d","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":3569282887853056,"repliedAuthor":{"id":3569282887853056,"idStr":"3569282887853056","authorId":3569282887853056,"name":"Princessleo","avatar":"https://community-static.tradeup.com/news/1145a6f471e451b1b446022e0eaed860","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"objectId":169623800,"type":1,"supId":4806780,"prevId":4806798,"content":"<u>Comment</u>","text":"<u>Comment</u>","html":"<u>Comment</u>"},{"id":4806798,"gmtCreate":1623833868681,"gmtModify":1635316705405,"authorId":3569282887853056,"author":{"id":3569282887853056,"idStr":"3569282887853056","authorId":3569282887853056,"name":"Princessleo","avatar":"https://community-static.tradeup.com/news/1145a6f471e451b1b446022e0eaed860","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":169623800,"type":1,"supId":4806780,"prevId":0,"content":"Yup","text":"Yup","html":"Yup"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":25,"commentSize":17,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}